Linagliptin, a selective DPP-4 inhibitor, inhibits DPP-4, increases incretin levels, lowers glucagon, and improves glycaemic control in patients with Type 2 diabetes.

T Rauch; U Graefe-Mody; Carolyn F. Deacon; A Ring; Jens Juul Holst; H-J Woerle; KA Dugi; T Heise

doi:10.1007/s13300-012-0010-y

Linagliptin, a selective DPP-4 inhibitor, inhibits DPP-4, increases incretin levels, lowers glucagon, and improves glycaemic control in patients with Type 2 diabetes.

T Rauch, U Graefe-Mody, Carolyn F. Deacon, A Ring, Jens Juul Holst, H-J Woerle, KA Dugi, T Heise

Endocrinology and Metabolism

37 Citations (Scopus)

Original language	English
Journal	Diabetes Therapy
Volume	3
Issue number	1
Pages (from-to)	10
ISSN	1869-6953
DOIs	https://doi.org/10.1007/s13300-012-0010-y
Publication status	Published - 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s13300-012-0010-y

Cite this

@article{44d67a0aab4045afbd3c7f0d7390df40,

title = "Linagliptin, a selective DPP-4 inhibitor, inhibits DPP-4, increases incretin levels, lowers glucagon, and improves glycaemic control in patients with Type 2 diabetes.",

author = "T Rauch and U Graefe-Mody and Deacon, {Carolyn F.} and A Ring and Holst, {Jens Juul} and H-J Woerle and KA Dugi and T Heise",

year = "2012",

doi = "10.1007/s13300-012-0010-y",

language = "English",

volume = "3",

pages = "10",

journal = "Diabetes Therapy",

issn = "1869-6953",

publisher = "Springer",

number = "1",

}

TY - JOUR

T1 - Linagliptin, a selective DPP-4 inhibitor, inhibits DPP-4, increases incretin levels, lowers glucagon, and improves glycaemic control in patients with Type 2 diabetes.

AU - Rauch, T

AU - Graefe-Mody, U

AU - Deacon, Carolyn F.

AU - Ring, A

AU - Holst, Jens Juul

AU - Woerle, H-J

AU - Dugi, KA

AU - Heise, T

PY - 2012

Y1 - 2012

U2 - 10.1007/s13300-012-0010-y

DO - 10.1007/s13300-012-0010-y

M3 - Journal article

SN - 1869-6953

VL - 3

SP - 10

JO - Diabetes Therapy

JF - Diabetes Therapy

IS - 1

ER -